Drug intelligence / Profile preview

CS12088

Development stage: Unknown
Lead developer: Akeso
Modality: Small Molecules

Overview

CS12088 is a small molecule HBV core assembly modulator (CAM) developed by Chipscreen Biosciences for the treatment of chronic hepatitis B. It functions by interfering with the assembly of the HBV nucleocapsid, which blocks the packaging of viral pre-genomic RNA (pgRNA) into the core. This action inhibits the replication of HBV DNA and the production of mature infectious viral particles. CS12088 is designed with liver-targeting properties to maximize antiviral efficacy while maintaining a favorable safety and tolerability profile.

Targets

HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on CS12088.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS12088.

Explore the full profile